Effect of Empagliflozin on Weight in Prediabetes and Diabetes
Author Information
Author(s): Sanjari Mojgan, Hadavizadeh Mohammad, Sadeghi Narges, Naghibzadeh-Tahami Ahmad
Primary Institution: Kerman University of Medical Sciences
Hypothesis
This study investigates the effect of empagliflozin on weight in patients with prediabetes and type 2 diabetes.
Conclusion
The weight, BMI, and waist circumference of patients decreased following the administration of empagliflozin.
Supporting Evidence
- The average weight of patients decreased by 2.96 kg (3.8%).
- BMI decreased by 1.10 kg/m² (3.72%).
- Waist circumference decreased by 3.23 cm.
- FPG decreased from 114.86 to 109.48 mg/dL.
- HbA1c decreased from 6.52% to 6.38%.
- Weight change was more significant in men than women.
- Weight reduction was greater in patients with GFR higher than 90.
Takeaway
This study found that taking a medication called empagliflozin helped people with prediabetes and diabetes lose weight.
Methodology
A quasi-experimental study where patients received 10 mg of empagliflozin daily for three months, with monthly evaluations of weight, BMI, waist circumference, and blood pressure.
Limitations
Small sample size, absence of a control group, and relatively short duration of follow-up.
Participant Demographics
43 participants (21 women and 22 men) aged 18 to 65 with prediabetes or type 2 diabetes.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website